BOSTON, Feb. 1, 2016 /PRNewswire/ -- Dana-Farber Cancer
Institute today announced an immuno-oncology collaboration with
potential applicability in a wide range of oncology indications
with Array BioPharma (NASDAQ: ARRY).
The research team at Dana-Farber's Robert and Renée Belfer
Center for Applied Cancer Science will work with Array scientists
on novel immune-oncology targets with the goal of bringing
innovative medicines to patients. The collaboration will leverage
the Belfer Center's proprietary immuno-oncology platform. Combining
Dana Farber's oncology expertise
with the Array's proficiency in drug discovery provides a unique
opportunity to accelerate drug discovery of effective medicines for
patients with unmet medical need.
"We are very enthusiastic about working with Array to develop
novel immune-oncology drugs because their team has a strong track
record of drug discovery success yielding innovative cancer
therapies. Together we have the potential to deliver novel
molecules that target unique mechanisms to harness the immune
system and result in durable efficacy," said Kwok-Kin Wong, MD,
PhD, scientific co-director of the Belfer Center for Applied Cancer
Science and Dana-Farber Cancer Institute, and professor of medicine
at Harvard Medical School.
"We are excited to partner with the Dana-Farber scientists at
the Belfer Center. Their capabilities perfectly synergize with
the capabilities and drug discovery track record of Array.
Specifically, their expertise in target validation, pre-clinical
models of immunotherapeutic activity and translational medicine
will greatly enable Array's ability to deliver innovative
therapeutics in this area," said Nick Saccomano, PhD, chief
scientific officer, Array BioPharma.
Financial terms of the agreement are not being disclosed.
About Dana-Farber Cancer Institute
From achieving the first remissions in childhood cancer with
chemotherapy in 1948, to developing the very latest new therapies,
Dana-Farber Cancer Institute is one of the world's leading centers
of cancer research and treatment. It is the only center
ranked in the top 4 of U.S. News and World Report's Best Hospitals
for both adult and pediatric cancer care.
Dana-Farber sits at the center of a wide range of collaborative
efforts to reduce the burden of cancer through scientific inquiry,
clinical care, education, community engagement, and advocacy.
Dana-Farber/Brigham and Women's Cancer Center provides the latest
in cancer care for adults; Dana-Farber/Boston Children's Cancer and
Blood Disorders Center for children. The Dana-Farber/Harvard Cancer
Center unites the cancer research efforts of five Harvard academic medical centers and two graduate
schools, while Dana-Farber Community Cancer Care provides high
quality cancer treatment in communities outside Boston's Longwood Medical Area.
Dana-Farber is dedicated to a unique, 50/50 balance between
cancer research and care, and much of the Institute's work is
dedicated to translating the results of its discovery into new
treatments for patients locally and around the world.
About Belfer Center for Applied Cancer Science
The Belfer Center for Applied Cancer Science is an
industry-inspired cancer research center integrated within the
Dana-Farber Cancer Institute dedicated to translating today's most
innovative oncology research into tomorrow's most promising cancer
treatments. We are accelerating the development of new cancer
treatment through work in the high-impact areas of immuno-oncology,
drug resistance, novel target discovery and blood-based biomarkers.
Partners of the Belfer Center gain access to a suite of
revolutionary platforms and capabilities that impact the success
and efficiency of preclinical and early clinical oncology
therapeutic development — from target identification to delineation
of clinical path for therapeutic agents. The Belfer Center's
portfolio of unique technologies and resources exists to help
academic and industry partners achieve success in developing and
bringing to market novel therapeutics for cancer.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on
the discovery, development and commercialization of targeted small
molecule drugs to treat patients afflicted with cancer. Six
registration studies are currently advancing related to three
cancer drugs. These programs include binimetinib (MEK162),
encorafenib (LGX818) and selumetinib (AstraZeneca). For more
information on Array, please go to www.arraybiopharma.com.
Forward-Looking Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements about the timing of the announcement of
the results of clinical trials for our proprietary and our
partnered programs, the timing of the completion or initiation of
further development of our wholly-owned and our partnered programs,
including the timing of regulatory filings, expectations that
events will occur that will result in greater value for Array, the
potential for the results of ongoing preclinical and clinical
trials to support regulatory approval or the marketing success of a
drug candidate, our ability to partner our proprietary drug
candidates for up-front fees, milestone and/or royalty payments,
our future plans to progress and develop our proprietary programs
and the plans of our collaborators to progress and develop programs
we have licensed to them, and our plans to build a late-stage
development company. These statements involve significant risks and
uncertainties, including those discussed in our most recent annual
report filed on Form 10-K, in our quarterly reports filed on Form
10-Q, and in other reports filed by Array with the Securities and
Exchange Commission. Because these statements reflect our current
expectations concerning future events, our actual results could
differ materially from those anticipated in these forward-looking
statements as a result of many factors. These factors include, but
are not limited to, our ability to continue to fund and
successfully progress internal research and development efforts and
to create effective, commercially-viable drugs; risks associated
with our dependence on our collaborators for the clinical
development and commercialization of our out-licensed drug
candidates; the ability of our collaborators and of Array to meet
objectives tied to milestones and royalties; our ability to
effectively and timely conduct clinical trials in light of
increasing costs and difficulties in locating appropriate trial
sites and in enrolling patients who meet the criteria for certain
clinical trials; risks associated with our dependence on
third-party service providers to successfully conduct clinical
trials within and outside the United
States; our ability to achieve and maintain profitability
and maintain sufficient cash resources; the extent to which the
pharmaceutical and biotechnology industries are willing to
in-license drug candidates for their product pipelines and to
collaborate with and fund third parties on their drug discovery
activities; our ability to out-license our proprietary candidates
on favorable terms; and our ability to attract and retain
experienced scientists and management. We are providing this
information as of February 1, 2016.
We undertake no duty to update any forward-looking statements to
reflect the occurrence of events or circumstances after the date of
such statements or of anticipated or unanticipated events that
alter any assumptions underlying such statements.
Contact:
Ellen Berlin,
Dana-Farber Cancer Institute
617-632-4090, ellen_berlin@dfci.harvard.edu
Tricia Haugeto, Array BioPharma
303-386-1193, thaugeto@arraybiopharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dana-farber-cancer-institutes-belfer-center-announces-immuno-oncology-research-collaboration-with-array-biopharma-300212422.html
SOURCE Array BioPharma